A Non-Interventional Post-Authorisation Safety Study (PASS) of Inotuzumab Ozogamicin to Characterize Complications Post-Hematopoietic Stem Cell Transplantation (HSCT) Following Inotuzumab Ozogamicin Treatment in Adult and Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL).

Study protocol

Initial protocol

INO PASS NI Study Protocol_FINAL

English (452.64 KB - PDF) View document

Study results

B1931028 Inotuzumab Final Study Report ABSTRACT 18FEB2023

English (130.44 KB - PDF) View document

Study report

B1931028 Inotuzumab Final Study Report 18Feb2023

English (3.09 MB - PDF) View document

B1931028 Inotuzumab Interim Report 2_20 Feb 2020 V1_Final

English (1.74 MB - PDF) View document

B1931028 Inotuzumab Interim Report 3 Final 17Feb2021

English (2.59 MB - PDF) View document

B1931028_INOTUZUMAB INTERIM REPORT 4 FINAL_18 FEB 2022

English (2.68 MB - PDF) View document

InO_Study B1931028_Interim report 1_FINAL

English (1.68 MB - PDF) View document

Other information

Study, other information

B1931028 Inotuzumab Interim Report 2_20 Feb 2020 V1_Final.pdf

English (1.74 MB - PDF) View document

B1931028 Inotuzumab Interim Report 3 Final 17Feb2021.pdf

English (2.59 MB - PDF) View document

B1931028_INOTUZUMAB INTERIM REPORT 4 FINAL_18 FEB 2022.pdf

English (2.68 MB - PDF) View document

InO_Study B1931028_Interim report 1_FINAL.pdf

English (1.68 MB - PDF) View document

Secondary tabs